Your browser doesn't support javascript.
loading
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato, Anthony R; Shah, Nirav N; Jurczak, Wojciech; Cheah, Chan Y; Pagel, John M; Woyach, Jennifer A; Fakhri, Bita; Eyre, Toby A; Lamanna, Nicole; Patel, Manish R; Alencar, Alvaro; Lech-Maranda, Ewa; Wierda, William G; Coombs, Catherine C; Gerson, James N; Ghia, Paolo; Le Gouill, Steven; Lewis, David John; Sundaram, Suchitra; Cohen, Jonathon B; Flinn, Ian W; Tam, Constantine S; Barve, Minal A; Kuss, Bryone; Taylor, Justin; Abdel-Wahab, Omar; Schuster, Stephen J; Palomba, M Lia; Lewis, Katharine L; Roeker, Lindsey E; Davids, Matthew S; Tan, Xuan Ni; Fenske, Timothy S; Wallin, Johan; Tsai, Donald E; Ku, Nora C; Zhu, Edward; Chen, Jessica; Yin, Ming; Nair, Binoj; Ebata, Kevin; Marella, Narasimha; Brown, Jennifer R; Wang, Michael.
Afiliação
  • Mato AR; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: matoa@mskcc.org.
  • Shah NN; Medical College of Wisconsin, Brookfield, WI, USA.
  • Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
  • Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital and University of Western Australia, Perth, WA, Australia.
  • Pagel JM; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA.
  • Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Fakhri B; Division of Hematology and Oncology, University of California, San Francisco, CA, USA.
  • Eyre TA; Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Lamanna N; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
  • Patel MR; Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA.
  • Alencar A; Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
  • Lech-Maranda E; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Wierda WG; MD Anderson Cancer Center, Houston, TX, USA.
  • Coombs CC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Gerson JN; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
  • Le Gouill S; Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.
  • Lewis DJ; University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Sundaram S; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Flinn IW; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
  • Tam CS; Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia.
  • Barve MA; Mary Crowley Cancer Research Center, Dallas, TX, USA.
  • Kuss B; Flinders University Medical Centre, Bedford Park, SA, Australia.
  • Taylor J; Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
  • Abdel-Wahab O; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lewis KL; Linear Clinical Research and Sir Charles Gairdner Hospital and University of Western Australia, Perth, WA, Australia.
  • Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Davids MS; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Tan XN; Linear Clinical Research and Sir Charles Gairdner Hospital and University of Western Australia, Perth, WA, Australia.
  • Fenske TS; Medical College of Wisconsin, Milwaukee, WI, USA.
  • Wallin J; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Tsai DE; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Ku NC; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Zhu E; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Chen J; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Yin M; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Nair B; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Ebata K; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Marella N; Loxo Oncology at Lilly, Stamford, CT, USA.
  • Brown JR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Wang M; MD Anderson Cancer Center, Houston, TX, USA. Electronic address: miwang@mdanderson.org.
Lancet ; 397(10277): 892-901, 2021 03 06.
Article em En | MEDLINE | ID: mdl-33676628
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Linfoma de Células B / Linfoma de Célula do Manto / Inibidores de Proteínas Quinases Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Linfoma de Células B / Linfoma de Célula do Manto / Inibidores de Proteínas Quinases Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article